about
The ocular surface epithelial barrier and other mechanisms of mucosal protection: from allergy to infectious diseasesAn overview of clinical and commercial impact of drug delivery systemsMEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applicationsTargeted and reversible blood-retinal barrier disruption via focused ultrasound and microbubblesUltrasound-enhanced delivery of antibiotics and anti-inflammatory drugs into the eye.Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.Mini drug pump for ophthalmic use.Synthesis and evaluation of a nanoglobular dendrimer 5-aminosalicylic Acid conjugate with a hydrolyzable schiff base spacer for treating retinal degeneration.Protection of retinal ganglion cells by caspase substrate-binding peptide IQACRG from N-methyl-D-aspartate receptor-mediated excitotoxicity.The potential of nanomedicine therapies to treat neovascular disease in the retina.Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.Multifunctional PEG retinylamine conjugate provides prolonged protection against retinal degeneration in mice.Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.Effective and sustained delivery of hydrophobic retinoids to photoreceptorsRecent applications of liposomes in ophthalmic drug delivery.Contribution of saccadic motion to intravitreal drug transport: theoretical analysis.Sustained subconjunctival protein delivery using a thermosetting gel delivery system.Novel nanoparticulate gel formulations of steroids for the treatment of macular edema.Evaluation of topical hesperetin matrix film for back-of-the-eye deliveryNovel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery ApplicationsMRI in ocular drug delivery.Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMDRecent perspectives in ocular drug delivery.Influence of drug lipophilicity on drug release from sclera after iontophoretic delivery of mixed micellar carrier system to human sclera.Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits.Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug deliveryThe use of canine models of inherited retinal degeneration to test novel therapeutic approaches.Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.Nanostructure-based platforms-current prospective in ophthalmic drug delivery.Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.Design of an implantable device for ocular drug delivery.The Effect of Diluted Penetration Enhancer in Nebulized Mist versus Liquid Drop Preparation Forms on Retrobulbar Blood Flow in Healthy Human Subjects.Current concepts in the treatment of retinitis pigmentosa.Alternative Drug Delivery for Patients Undergoing Cataract Surgery as Demonstrated in a Canine Model.Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab.
P2860
Q26865809-66B850AF-68A7-46E4-AAD8-BFE7BAD0CA96Q27007143-EA834339-1A15-4180-97E9-67DA3796BE60Q27022363-0561E0F4-F7AA-4490-A838-68ECDA223558Q28482229-E1C064A0-423C-4C9D-B5D3-85B4495ADDC9Q30441010-95361A11-29E2-4B07-A653-2D684B9AA8E6Q33558455-48E7A71B-8BB0-48F7-B1E4-249B84BC9527Q33623415-9D12F946-AF79-48CA-A4DB-73F4D0B62291Q33768680-462DB6E5-33FB-43F2-903B-29F800750577Q33845365-0CA1F7A2-709C-4C56-AFCF-A050AAF8C160Q34220590-9BD268EE-FFCE-4067-86AE-47251A421BCDQ34422585-48F7561D-5C2A-4AAA-8248-2840BBF93A42Q34669685-0D6D10AF-91F5-4973-8F55-C1F002E021D0Q34701929-4F5F454F-F072-4304-81FD-B56C8306FCCBQ34702182-C4939F6D-E2EA-48DB-99CA-EEB213FBA811Q34734683-3F09C4D8-4E7A-4DD0-A10B-A72CF0CBB490Q34778859-013BB11A-1EC6-45D2-84CE-CE276082E5E0Q34987321-C0ABFF3E-C085-4C47-97B2-482891329ED4Q34987327-20D2EDC0-8377-4A46-9ADB-85AA4525766FQ35602734-FCAC1B1C-BA3D-49A3-B56C-EC5DFD8C13B2Q35696092-34A56AC4-5913-45D4-B6B5-910858FF614AQ35759073-FFB4A904-9C57-45F5-B029-DD19E5C76386Q36985582-17F90787-472A-4226-84BE-1777F5A0CA50Q37054230-9E39CC83-53A0-4848-A40F-C240024603A8Q37166978-F7490805-11CD-4EDF-AAEF-0D69B1404FD5Q37256549-7A96EC5B-05F7-4788-B7D8-E7C21415C12DQ37274226-4B0CEDEB-EF40-4496-938C-F658E08E3558Q37354471-AC281C05-3B5A-4D68-81F9-5EFB2E1156F7Q37396059-E0E2FB52-3B79-4AF5-97DD-CEB212D65791Q37458980-1C800F68-A7AC-4A54-ACCA-98B8A344CB8EQ37731143-6D1A9E24-B651-4F13-8ED6-EF1C43CDA100Q38239355-901B8A79-AC09-427E-AA70-6606CCFFED22Q38716544-0C3241F4-113E-4843-85C2-E1AAA2E0833CQ39564169-8DC762B9-2781-4CA4-A0BD-860CDE2D7AF8Q41988607-ADA7F35F-1403-4634-8C21-1BEE291A0893Q42105112-B2B78290-AB34-4C52-AB7D-0DE56D86DD12Q46545095-30B0FB87-1E7E-44B8-A9B9-620EDEC376E4Q47156996-907E2217-FC77-4913-B186-8FA24E066878
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Drug delivery for posterior segment eye disease.
@ast
Drug delivery for posterior segment eye disease.
@en
type
label
Drug delivery for posterior segment eye disease.
@ast
Drug delivery for posterior segment eye disease.
@en
prefLabel
Drug delivery for posterior segment eye disease.
@ast
Drug delivery for posterior segment eye disease.
@en
P1476
Drug delivery for posterior segment eye disease.
@en
P2093
Edelhauser HF
Geroski DH
P304
P407
P577
2000-04-01T00:00:00Z